## Alkem Laboratories Limited (ALKEM) Stock Analysis - December 20, 2024

This report analyzes Alkem Laboratories Limited (ALKEM) stock data to provide a buy, sell, or hold recommendation.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                     |
|-----------------|--------------------------|
| Symbol           | ALKEM                    |
| Company Name     | Alkem Laboratories Limited |
| Industry         | Pharmaceuticals           |
| Listing Date     | 2015-12-23                |
| ISIN             | INE540L01014              |


**1.2 Market Data:**

| Metric                | Value     |
|-----------------------|------------|
| Last Price            | 5,425.00   |
| Change                | -69.25     |
| % Change              | -1.26%     |
| Previous Close        | 5,494.25   |
| Open                  | 5,535.00   |
| Close                 | 5,427.50   |
| VWAP                  | 5,468.69   |
| Week High             | 6,439.90   |
| Week Low              | 4,407.05   |
| Sector PE             | 29.68      |
| Symbol PE             | 30.4       |
| Total Traded Volume   | 1.13       | (in unspecified units, likely millions)
| Delivery Quantity     | 56,981     | (in unspecified units)
| Delivery to Traded % | 50.38%     |


**1.3 Corporate Actions:**

| Ex-Date      | Purpose                                      |
|--------------|----------------------------------------------|
| 09-Aug-2024  | Dividend - Rs 5 Per Share                     |
| 16-Feb-2024  | Interim Dividend - Rs 35 Per Share             |
| 10-Aug-2023  | Dividend - Rs 10 Per Share                    |
| 17-Feb-2023  | Interim Dividend - Rs 15 & Special Rs 25 Per Share |
| ...           | ... (Further historical dividend data available) |


**1.4 Recent Announcements (Last 8):**

| Broadcast Date | Subject                                         |
|-----------------|-------------------------------------------------|
| 18-Dec-2024    | Copy of Newspaper Publication                   |
| 17-Dec-2024    | Acquisition-XBRL                               |
| 17-Dec-2024    | General Updates                                  |
| 11-Dec-2024    | Action(s) initiated or orders passed             |
| 10-Dec-2024    | Slump Sale-XBRL                                 |
| 10-Dec-2024    | Analysts/Institutional Investor Meet/Con. Call Updates |
| 10-Dec-2024    | General Updates                                  |
| 03-Dec-2024    | Analysts/Institutional Investor Meet/Con. Call Updates |


**1.5 Financial Results (Last Five Quarters):**

| Quarter End    | Income      | Expenditure | Profit After Tax | Diluted EPS |
|----------------|-------------|-------------|-----------------|-------------|
| 30-Sep-2024   | 299,216     | 222,449     | 69,758           | 58.34        |
| 30-Jun-2024   | 260,620     | 196,526     | 58,325           | 48.78        |
| 31-Mar-2024   | 244,916     | 204,763     | 32,497           | 27.18        |
| 31-Dec-2023   | 259,025     | 200,456     | 50,423           | 42.17        |
| 30-Sep-2023   | 269,643     | 205,771     | 64,651           | 54.07        |


**(Note:  All financial figures are in unspecified currency units.  The provided data does not specify the currency.)**


**1.6 Shareholding Patterns:**

| Quarter End    | Promoter & Promoter Group | Public |
|----------------|--------------------------|--------|
| 30-Sep-2024   | 55.66%                     | 44.34% |
| 30-Jun-2024   | 56.38%                     | 43.62% |
| 31-Mar-2024   | 56.74%                     | 43.26% |
| 31-Dec-2023   | 56.74%                     | 43.26% |
| 30-Sep-2023   | 56.74%                     | 43.26% |


**1.7 Board Meetings (Recent):**

| Meeting Date | Purpose                                                                     |
|--------------|-----------------------------------------------------------------------------|
| 13-Nov-2024  | To consider and approve unaudited financial results for the half-year ended Sep 2024 |
| 09-Aug-2024  | To consider and approve financial results for the period ended June 30, 2024     |
| 29-May-2024  | To consider and approve financial results for the period ended March 31, 2024   |
| ...           | ... (Further historical board meeting data available)                       |


**1.8 Key Management Personnel (Partial List):**

| Name                 | Designation                     |
|----------------------|---------------------------------|
| Basudeo N. Singh      | Chairperson Related To Promoters, Executive Director |
| Sandeep Singh         | Executive Director-MD            |
| ...                   | ... (Further director data available) |


**1.9 Contact Information:**

* **Registrar:** Link Intime India Pvt. Ltd.
* **Company Contact:** investors@alkem.com, www.alkemlabs.com


**2. Key Indicators:**

**2.1 Current Price Analysis:**

* The current price (5,425.00) is below the previous close (5,494.25), indicating a downward trend.
* It's also below the pre-open IEP (5,535.00).
* However, it's significantly above the week's low (4,407.05) and well within the week's high and low range.

**2.2 Financial Performance:**

* Revenue shows some fluctuation over the last five quarters, but generally remains relatively stable.
* Profit after tax and diluted EPS show a downward trend in the last quarter (Q3 FY25), but remain positive.  This needs further investigation to determine if this is a temporary blip or a concerning trend.

**2.3 Shareholding Analysis:**

* Promoter holding has decreased slightly from 56.74% to 55.66% over the last year, which might indicate some selling pressure.  This decrease warrants further investigation into the reasons behind the reduction.

**2.4 Corporate Action Summary:**

* The company has a history of consistent dividend payouts, both interim and final, indicating a commitment to returning value to shareholders.  The recent dividend of Rs 5 per share is a positive sign.

**2.5 Volatility and Risk:**

* The provided data shows a CM Daily Volatility of 1.56% and a CM Annual Volatility of 29.8%.  This suggests moderate to high volatility, indicating a higher risk profile for the stock.

**2.6 Key Directors and Contact Info:**  (See Section 1.8 and 1.9 above)


**3. Final Verdict:**

Based on the provided data, the recommendation is **Hold**.

**Reasoning:**

* While the company shows a history of consistent dividend payouts and generally stable revenue, the recent decline in profit after tax and diluted EPS in Q3 FY25, coupled with a slight decrease in promoter holdings, raises some concerns.  The high volatility also adds to the risk.  More information is needed to determine if the Q3 decline is a temporary anomaly or the start of a negative trend.  Further investigation into the reasons for the decrease in promoter holdings is also necessary.

**Conclusion:**

Alkem Laboratories Limited presents a mixed picture.  While the dividend history and generally stable revenue are positive, the recent dip in profitability and the decrease in promoter holdings warrant a cautious approach.  A "Hold" recommendation allows for further observation and data gathering before making a more decisive investment decision.  Investors should monitor the company's performance in the coming quarters and investigate the reasons behind the recent decline in profitability and promoter holdings before considering a buy or sell decision.
